Absci Corporation ABSI

Company Overview

Absci Corporation is a U.S.-based biotechnology and artificial intelligence company focused on drug discovery and biologics development. The company operates at the intersection of generative AI, synthetic biology, and antibody engineering, with a primary emphasis on accelerating the discovery and optimization of therapeutic antibodies. Absci’s platform is designed to integrate AI-driven target identification, de novo antibody design, and wet-lab validation into a unified discovery workflow intended to shorten development timelines and improve the probability of clinical success.

The company’s core business is centered on its AI-powered drug creation platform and collaborations with pharmaceutical and biotechnology companies. Revenue has historically been generated through research partnerships, licensing arrangements, milestone payments, and technology-enabled discovery agreements. Absci was founded in 2011 and evolved from a synthetic biology and protein expression technology company into an AI-focused biologics discovery enterprise following acquisitions and internal platform expansion. The company became publicly traded through a merger with a special purpose acquisition company in 2021.